Redeye comments of Eniro Groups Q3 report, were revenue and EBITDA were published by the company 16t...
Redeye concludes that the Q3 report came in right on its estimates on practically all fronts - imply...
Redeye provides its initial take on Surgical Science’s Q3 2023 report, which came in broadly below o...
Redeye has reviewed its Company Quality Rating, which results in a somewhat lowered WACC, rendering ...
Redeye strengthens its positive view of Vertiseit following a strong Q3, with significant improvemen...
Redeye makes minor changes to its fair value range following Xspray Pharma’s Q3 report, which contai...
Sales +1% and adj. EBITA +28% vs. ABGSCe Improved factory efficiency leads to higher profitability C...
Under det tredje kvartalet 2023 har Future Gaming Group (”FGG” eller ”Bolaget”) gjort om villkoren f...
With the new information about the development plan of fostrox in liver cancer, we update our base c...
Redeye believes Zwipe had no choice but to bring in capital through another rights issue.
Redeye updates its estimates and valuation following Freemelt’s Q3 report, which came in somewhat we...
Redeye updates its estimates after reviewing Fantasma Games’ Q3 report, which showed lower growth th...
2023-25e earnings forecasts raised by 3-64%... ...due to the sale of International, strong developme...
Sales SEK 8.2m, up 2% y-o-y: one delivery, two orders First eMELT delivery in '24e now highly likely...
Aspo sells 15.4% of its ESL Shipping segment for EUR 30m to OP Suomi Infra Ky.
Sales in line, write-down of advances weighed on EBIT, FCF solid We cut '23e-'25e adj.
Kammac provides attractive niche exposure... ...and looks highly accretive on multiple and earnings ...
Under det tredje kvartalet 2023 har Spotlight Group (”Spotlight” eller ”Bolaget”) fått godkänt bytet...
Rapportkommentar OncoZenge släppte under förra veckan sin rapport för det tredje kvartalet.
Klartecken för Tumorad Det finansiella i rapporten för det tredje kvartalet bjöd inte på några störr...
